MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has been granted a U.S. patent for the use of its leading compound, buntanetap, ...

Annovis Bio’s buntanetap receives US patent for treatment and prevention of acute brain or nerve injuries: Malvern, Pennsylvania Thursday, January 16, 2025, 17:00 Hrs [IST] Anno ...

Annovis Bio (ANVS) announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain ...

Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's. The company is developing innovative therapies that ...

Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative ...

In recent trading, Annovis Bio Inc (ANVS) stock price has shown some volatility, fluctuating -0.59% over the last five trades and -13.2 ...

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Annovis Bio (ANVS – Research Report), retaining the price target of $25.00. Discover outperforming stocks and invest smarter with ...

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced that the U.S. Food and Drug Administration (FDA) has accepted an updated protocol for the company’s pivotal Phase 3 Alzheimer’s (AD) ...

MALVERN, Pa. - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company focused on neurodegenerative diseases with a market capitalization of $74 million, announced today that the U.S.

(RTTNews) - Annovis Bio, Inc. (ANVS), a clinical-stage biotechnology company, announced on Tuesday that the FDA has accepted its updated protocol for the pivotal Phase 3 Alzheimer's Disease or AD ...